Aligos Therapeutics, Inc. - ALGS
About Gravity Analytica
Recent News
- 02.12.2025 - Aligos Therapeutics Announces $105 Million Private Placement Financing
- 12.13.2024 - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 12.03.2024 - Evercore ISI 7th Annual HealthCONx Conference
- 12.03.2024 - Piper Sandler 36th Annual Healthcare Conference
- 11.26.2024 - Aligos Therapeutics to Present at Investor Conferences in December
- 11.22.2024 - The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075
- 11.19.2024 - Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
- 11.19.2024 - Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
- 11.19.2024 - ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
- 11.19.2024 - ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2